[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571982":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":76,"collaborators":30,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":30,"enrollmentInfo":88,"targetDuration":30,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":30,"overallStatus":60,"whyStopped":30,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tirzepatide","EXPERIMENTAL","This arm will receive tirzepatide (n=10) weekly 2.5mg injections for 4 weeks.",[13],"Drug: Tirzepatide",{"label":15,"type":16,"description":17,"interventionNames":18},"Saline Placebo","PLACEBO_COMPARATOR","This arm will receive saline placebo injections (n=10) weekly for 4 weeks.",[19],"Other: Saline Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","This intervention will consist of the FDA-approved dosing schedule. Participants will receive 2.5mg weekly injections for 4 weeks. IDS will extract tirzepatide and draw the doses into syringes.",[9],[26],"Mounjaro",{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo syringes of saline and matching volume will be produced by IDS.",[15],null,[32],{"name":33,"affiliation":5,"role":34},"Joji Suzuki, MD","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":30,"email":39},"CONTACT","617-732-5752","jsuzuki2@bwh.harvard.edu",{"name":41,"role":37,"phone":42,"phoneExt":30,"email":43},"Laura M Holsen, Ph.D.","617-525-8772","lholsen@bwh.harvard.edu",[45,58],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":30},"ACTIVE_NOT_RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-71.05977,42.35843,{"lat":56,"lon":55},{"facility":59,"status":60,"city":61,"state":48,"zip":62,"country":50,"countryCode":51,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Brigham and Women's Faulkner Hospital","RECRUITING","Jamaica Plain","02130",{"type":53,"coordinates":64},[65,66],-71.12033,42.30982,{"lat":66,"lon":65},[69,70,73,74],{"name":33,"role":37,"phone":38,"phoneExt":30,"email":39},{"name":71,"role":37,"phone":30,"phoneExt":30,"email":72},"Jeong Hoo (Eric) Lee, MD","jlee351@bwh.harvard.edu",{"name":33,"role":34,"phone":30,"phoneExt":30,"email":30},{"name":71,"role":75,"phone":30,"phoneExt":30,"email":30},"SUB_INVESTIGATOR",{"type":34,"investigatorFullName":33,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Director, Division of Addiction Psychiatry","100571982","phase-2-study-of-tirzepatide-for-recovery-and-alcohol-use-management-100571982",false,"NCT06727331","Study of Tirzepatide for Recovery and Alcohol Use Management","Tirzepatide for the Treatment of Alcohol Use Disorder: A Pilot Randomized Controlled Trial","STREAM","Inclusion Criteria:\n\n* English speaking adults aged 18 and above\n* Diagnosed with current DSM-5 alcohol use disorder\n* Willing and able to physically travel to BWH CCI outpatient facilities for study visits\n\nExclusion Criteria:\n\n* CIWA score at screening ≥ 8.\n* Psychotic disorder, active suicidality or homicidality or any psychiatric condition that impair ability to provide informed consent\n* Any lifetime diagnosis of eating disorders including anorexia, bulimia, binge eating, or avoidant\u002Frestrictive food intake disorder\n* BMI\\\u003C23 mg\u002Fkg2\n* Current or lifetime diagnosis of Type 1 or Type 2 diabetes\n* Current (or within 30 days of enrollment) use of any anti-obesity medications or medications with glucose lowering properties (including GLP-1 analogues, sulfonylurea, insulin, metformin, thiazolidinediones, dipeptidyl peptidase-4 (DPP-IV) inhibitors, or sodium-glucose cotransporter-2 (SGLT-2) inhibitors)\n* Use of any GLP-1 agonist medications in the prior 3 months\n* Anticipating receipt of any other GLP-1 agonist medications during the trial\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n* Current hypoglycemia as indicated by a blood sugar level of ≤70 mg\u002FdL measured at the baseline visit\n* Calcitonin ≥ 50 ng\u002FL\n* Triglycerides ≥500 mg\u002FdL\n* Untreated cholelithiasis or gallbladder disease\n* Acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or congestive heart failure in the last 90 days\n* Uncontrolled hypertension at baseline, as indicated by an average blood pressure reading of \\>180\u002F110 after three successive readings\n* History of inflammatory bowel disease, bariatric surgery, pancreatitis, diabetic gastroparesis, or non-arteritic anterior ischemic optic neuropathy\n* Liver function test greater than 5 times upper normal limit\n* Renal impairment as indicated by eGFR of \\\u003C30\n* History of hypersensitivity or allergy to tirzepatide\n* Pregnant or breastfeeding\n* Anticipated to be enrolled in another clinical drug trial during participation in this trial\n* Any other reason or clinical condition that the investigators judge may interfere with study participation and\u002For be unsafe for a participant","ALL","18 Years",{"count":89,"type":90},20,"ESTIMATED","INTERVENTIONAL",[93],"PHASE2","This is a pilot, 4-week, double-blind, placebo-controlled, randomized trial of individuals with alcohol use disorder (AUD) to receive weekly injections of either tirzepatide (n=10) or matching placebo (n=10). The primary aim is to determine the effects of tirzepatide on cue-reactivity among individuals with AUD. The secondary aim is to assess the safety and preliminary efficacy of tirzepatide for AUD.",[96],"Alcohol Use Disorder (AUD)","2026-07-07",{"date":99,"type":100},"2026-07-09","ACTUAL",{"date":102,"type":100},"2025-09-15",{"date":104,"type":90},"2027-07-01",{"name":5,"class":6},2]